MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering price per share of $10.50. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be approximately $75 million. The offering is expected to close on or about November 6, 2025, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.